10% owner ARCH Venture Fund XIII, L.P. adds $25M of Lyell Immunopharma, Inc. stock
The 10% owner paid an average of $10.77 a share, according to a Form 4 filed with the SEC on Nov 5.
ARCH Venture Fund XIII, L.P., a holder of more than 10% of Lyell Immunopharma, Inc. (LYEL), bought 2,321,262 shares on Nov 4 at an average price of $10.77, a total of $25 million, according to a Form 4 filed on Nov 5.
The filing reports the shares as held indirectly, for example through a trust or a fund. With this purchase the insider holds 3,747,790 shares, 163% more than before.
The trade was reported within two business days, as Section 16 requires.
Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.
| Company | Lyell Immunopharma, Inc. (LYEL) |
|---|---|
| Insider | ARCH Venture Fund XIII, L.P. |
| Role | 10% owner |
| Transaction | Open-market purchase (code P) |
| Shares | 2,321,262 |
| Average price | $10.77 |
| Value | $24,999,992 |
| Trade date | Nov 4, 2026 |
| Filed with the SEC | Nov 5, 2026, 5:34 PM ET |
| Shares held after | 3,747,790 |
| Ownership | Indirect |
| Rule 10b5-1 plan | Not marked in the filing |
See the detailed report on this LYEL purchase
Follow LYEL for the next insider trade · See all the latest insider trades
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.
